



**Dominik Wolf**

**Contact**

Dominik Wolf

## Publications (16)

Bösch M, Horvath L, Baty F, Pircher A, Wolf D, Spahn S, Straussman R, Tilg H, Brutsche M. Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects. *J Immunother Cancer* 2022; 10

Boesch M, Baty F, Kowatsch T, Wolf D, Früh M, Brutsche M. Call for a holistic framework for cancer immunotherapy. *Cancer* 2022; 128:3772–3774.

Wolf D, Reimer D, Hartmann G, Sopper S, Sprung S, Marth C, Wieser V, Zeimet A, Fiegl H, Bösch M. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. *Int J Cancer* 2019

Bösch M, Baty F, Rumpold H, Sopper S, Wolf D, Brutsche M. Fibroblasts in cancer: Defining target structures for therapeutic intervention. *Biochim Biophys Acta Rev Cancer* 2019; 1872:111–121.

Hatina J, Bösch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet A. Ovarian Cancer Stem Cell Heterogeneity. *Adv Exp Med Biol* 2019; 1139:201–221.

Bösch M, Reimer D, Wolf D, Hatina J, Rössler J, Wiedemair A, Fiegl H, Marth C, Sopper S, Zeimet A. Evaluation of Vav3.1 as prognostic marker in endometrial cancer. *J Cancer Res Clin Oncol* 2018; 144:2067–2076.

Bösch M, Reimer D, Sopper S, Wolf D, Zeimet A. (Iso-)form Matters: Differential Implication of Vav3 Variants in Ovarian Cancer. *Oncologist* 2018; 23:757–759.

Reimer D, Hackl H, Parson W, Altevogt P, Hatina J, Sopper S, Marth C, Wolf D, Bösch M, Zeimet A. Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response. *Int J Cancer* 2017; 142:1640–1651.

Bösch M, Hoflehner E, Wolf D, Gastl G, Sopper S. Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples. *J Vis Exp* 2017

Bösch M, Sopper S, Zeimet A, Reimer D, Gastl G, Ludewig B, Wolf D. Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche. *Biochim Biophys Acta* 2016; 1866:276–289.

Bösch M, Sopper S, Wolf D. Ionophore Antibiotics as Cancer Stem Cell-Selective Drugs: Open Questions. *Oncologist* 2016; 21:1291–1293.

Bösch M, Zeimet A, Fiegl H, Wolf B, Huber J, Klocker H, Gastl G, Sopper S, Wolf D. High prevalence of side population in human cancer cell lines. *Oncoscience* 2016; 3:85–87.

Bösch M, Wolf D, Sopper S. Optimized Stem Cell Detection Using the DyeCycle-Triggered Side Population Phenotype. *Stem Cells Int* 2015; 2016:1652389.

Bösch M, Zeimet A, Rumpold H, Gastl G, Sopper S, Wolf D. Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics. *Stem Cells Transl Med* 2015; 4:1028–32.

**Bösch M, Wolf D, Hatina J, Spoeck F, Parson W, Gastl G, Schmidt S, Reimer D, Zeimet A, Sopper S. The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. *Oncotarget* 2014; 5:7027-39.**

**Bösch M, Reimer D, Rumpold H, Zeimet A, Sopper S, Wolf D. DyeCycle Violet used for side population detection is a substrate of P-glycoprotein. *Cytometry A* 2012; 81:517-22.**

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)